Nanosizing--oral formulation development and biopharmaceutical evaluation.
about
Nanomilling of Drugs for Bioavailability Enhancement: A Holistic Formulation-Process Perspective.Nanosizing of drugs: Effect on dissolution ratePharmaceutical Cocrystals: Regulatory and Strategic Aspects, Design and DevelopmentPolymer Encapsulation of an Amorphous Pharmaceutical by initiated Chemical Vapor Deposition for Enhanced StabilityAn Intensified Vibratory Milling Process for Enhancing the Breakage Kinetics during the Preparation of Drug Nanosuspensions.The relevancy of controlled nanocrystallization on rifampicin characteristics and cytotoxicity.Evaluation of Stability and Biological Activity of Solid Nanodispersion of Lambda-Cyhalothrin.Custom fractional factorial designs to develop atorvastatin self-nanoemulsifying and nanosuspension delivery systems--enhancement of oral bioavailabilityClarithromycin dissolution enhancement by preparation of aqueous nanosuspensions using sonoprecipitation technique.Fabrication of carvedilol nanosuspensions through the anti-solvent precipitation-ultrasonication method for the improvement of dissolution rate and oral bioavailability.Downscaling drug nanosuspension production: processing aspects and physicochemical characterization.Particle size reduction for improvement of oral absorption of the poorly soluble drug UG558 in rats during early development.Discovery, synthesis, and optimization of antimalarial 4(1H)-quinolone-3-diarylethers.Fabrication, characterization and in vitro evaluation of silibinin nanoparticles: an attempt to enhance its oral bioavailabilityPreparation, characterization and pharmacokinetics of cyadox nanosuspension.Nanosizing of a poorly soluble drug: technique optimization, factorial analysis, and pharmacokinetic study in healthy human volunteers.Influence of particle size on the ultraviolet spectrum of particulate-containing solutions: implications for in-situ concentration monitoring using UV/Vis fiber-optic probes.Continuous production of drug nanoparticle suspensions via wet stirred media milling: a fresh look at the Rehbinder effect.Oridonin nanosuspension was more effective than free oridonin on G2/M cell cycle arrest and apoptosis in the human pancreatic cancer PANC-1 cell lineAnalytical methods for dissolution testing of nanosized drugs.A silica-based pH-sensitive nanomatrix system improves the oral absorption and efficacy of incretin hormone glucagon-like peptide-1Summary report of PQRI Workshop on Nanomaterial in Drug Products: current experience and management of potential risks.Preparation and optimization of resveratrol nanosuspensions by antisolvent precipitation using Box-Behnken designProduction, characterisation, and in vitro nebulisation performance of budesonide-loaded PLA nanoparticles.Arsenic in cancer treatment: challenges for application of realgar nanoparticles (a minireview).Pharmacokinetic evaluation of fosaprepitant dimeglumineElucidating the in vivo fate of nanocrystals using a physiologically based pharmacokinetic model: a case study with the anticancer agent SNX-2112.Nitrendipine nanocrystals: its preparation, characterization, and in vitro-in vivo evaluation.Is the combination of cellulosic polymers and anionic surfactants a good strategy for ensuring physical stability of BCS Class II drug nanosuspensions?Enhancement of cellular uptake, transport and oral absorption of protease inhibitor saquinavir by nanocrystal formulation.Formulation and optimization of solid lipid nanoparticle formulation for pulmonary delivery of budesonide using Taguchi and Box-Behnken designFormulation of nimodipine nanocrystals for oral administration.Ultra rapidly dissolving repaglinide nanosized crystals prepared via bottom-up and top-down approach: influence of food on pharmacokinetics behavior.Challenges and opportunities in achieving bioequivalence for fixed-dose combination products.Morphology, in vivo distribution and antitumor activity of bexarotene nanocrystals in lung cancer.Effect of particle size on solubility, dissolution rate, and oral bioavailability: evaluation using coenzyme Q₁₀ as naked nanocrystals.Eudragit-based nanosuspension of poorly water-soluble drug: formulation and in vitro-in vivo evaluationAminoclay-lipid hybrid composite as a novel drug carrier of fenofibrate for the enhancement of drug release and oral absorption.Oral bioavailability of cantharidin-loaded solid lipid nanoparticlesTherapeutic surfactant-stripped frozen micelles.
P2860
Q26746912-DCE0FC6F-B055-4027-A3FB-C3F3BB4BA43DQ26781058-6D35277A-6494-4DA0-A1B4-9F42367CC86EQ28468556-55819E1D-4D15-4216-8FEE-2F80F0FAAF65Q28828863-8B1CA99C-7525-4C96-A1FA-09674514C6D9Q30375813-CFD27AAA-181B-4FBB-A350-C061D8CBCD44Q30381972-E4509A92-9D6C-43DB-A0BC-9C3435DC2476Q30387849-AA5D4A0F-34DF-4539-BDA9-AD8BF958320FQ30407466-B62F5BBE-C8F2-4078-8DB3-907C644CB6DBQ30430057-D385CB0C-FFD2-4248-8BDC-E4F8BABFB18EQ30459146-CB71C51C-EBA9-4F1E-84E9-0A9020144516Q30478736-EDD3E70F-71C8-4879-8904-7D2EF20AC678Q30903645-4A6A663D-4188-427B-AAD5-FFFCA1A1D402Q33599811-B52BA1EF-9010-4FFA-8D68-89B8F64A2B16Q33713924-9E2D65E5-998D-4B98-B205-F2DD0828FB31Q33720079-17BE8DC3-ADCC-47E3-B4BA-B24764295439Q33800631-10769017-30DB-4BC9-A18F-21D550CE4208Q33837006-1C3B98C9-AB88-4398-AA8E-DC4F7E1C4CB9Q34232283-B02D3CE3-AE32-4D79-8866-BA33E505D422Q34278726-ABDFCD68-2D18-44F4-8BC2-852D66E7AECFQ34299947-03FA39D3-AB81-4FAF-BE0F-D28CD4D7F474Q34426261-F756FA10-94EA-4BAC-9507-C23A1868F744Q34871881-445C1DB3-59EF-46DE-A434-DBB217152C7EQ35024394-D45BEB23-6C17-4534-8213-F4FC1C861F47Q35138923-32263FE0-FCA6-4675-BD2A-7D5AE0828817Q35155855-FA9D395C-30AF-46F1-8E5B-356E97DCDC27Q35163168-1539D74A-C991-4B57-943B-85849B6B9DF3Q35284235-40EF31D2-967E-4915-8A06-F1784DE5723DQ35577252-E0A010BD-014E-4502-A4BB-152B1722509DQ35578230-E3CD4102-AF65-4D62-B340-752CFE56F4C4Q35740855-9E060D94-DE99-4296-9B8E-2C595FA32458Q35796474-AB208E34-F805-4D87-9CB8-52448529941BQ35846349-4F90A6DA-68D8-4E7B-912E-C9F6452B0544Q35868308-4F0A063E-32CD-48CC-A73F-99133DE63C83Q36065586-EFA14AC3-3693-4772-B5C4-45EF5EC42280Q36121396-624D0D09-9B25-4DC5-A074-138DAC71B446Q36404933-73A6012D-0A64-462E-B514-2DEB73871487Q36442159-C5F6EC19-00DF-415F-96EF-D74D660B7744Q36710243-5CE3B65F-60D5-40E7-978A-91AE8DCA1776Q36738802-F2B7745A-93BD-4990-8715-E02603A722F9Q36919868-2D35F1A7-6C12-4292-B2C1-A26F062095B4
P2860
Nanosizing--oral formulation development and biopharmaceutical evaluation.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Nanosizing--oral formulation development and biopharmaceutical evaluation.
@en
type
label
Nanosizing--oral formulation development and biopharmaceutical evaluation.
@en
prefLabel
Nanosizing--oral formulation development and biopharmaceutical evaluation.
@en
P2093
P1476
Nanosizing--oral formulation development and biopharmaceutical evaluation.
@en
P2093
Filippos Kesisoglou
Santipharp Panmai
P304
P356
10.1016/J.ADDR.2007.05.003
P407
P577
2007-05-25T00:00:00Z